Clinical characteristics of drug-induced liver injury and related risk factors

Experimental and Therapeutic Medicine

Volumn 12, Issue 4, 2016, Pages 2606-2616

  Lu, Ren Jie ^a   Zhang, Yan ^a   Tang, Feng Lei ^a   Zheng, Zhong Wei ^a   Fan, Zheng Da ^a   Zhu, Shan Mei ^a   Qian, Xian Feng ^a   Liu, Na Na ^a  

^a The Third People s Hospital of Changzhou   (China)

Author keywords

Clinical feature; Drug induced liver injury; Pathogenesis; Risk factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; BILIRUBIN; CHINESE DRUG; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CHOLESTATIC HEPATITIS; DIABETES MELLITUS; FALLOPIA MULTIFLORA; FEMALE; FEVER; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PROTHROMBIN TIME; RASH; RETROSPECTIVE STUDY; RISK FACTOR; TOXIC HEPATITIS; TRIPTERYGIUM WILFORDII;

EID: 84988027239     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3627     Document Type: Article

References (25)

1. Larrey D: Drug-induced hepatitis: Epidemiologic, clinical, diagnostic and physiopathologic aspects in 1995. Rev Med Interne 16: 752-758, 1995 (In French).
2. Kaplowitz N: Drug-induced liver injury. Clin Infect Dis 38 (Suppl 2): S44-S48, 2004.
3. Russmann S, Jetter A and Kullak-Ublick GA: Pharmacogenetics of drug-induced liver injury. Hepatology 52: 748-761, 2010.
4. McGill MR and Jaeschke H: MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J Clin Med 4: 1063-1078, 2015.
5. Ward J, Kanchagar C, Veksler-Lublinsky I, Lee RC, McGill MR, Jaeschke H, Curry SC and Ambros VR: Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA 111: 12169-12174, 2014.
6. Danan G and Benichou C: Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 46: 1323-1330, 1993.
7. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-González JF, et al; Spanish Group for the Study of Drug-Induced Liver Disease: Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology 49: 2001-2009, 2009.
8. Chalasani N and Björnsson E: Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138: 2246-2259, 2010.
9. Zhu Y, Li YG, Wang JB, Liu SH, Wang LF, Zhao YL, Bai YF, Wang ZX, Li JY and Xiao XH: causes, features, and outcomes of drug-induced liver injury in 69 children from China. Gut Liver 9: 525-533, 2015.
10. Ma X, Peng JH and Hu YY: Chinese Herbal Medicine-induced Liver Injury. J Clin Transl Hepatol 2: 170-175, 2014.
11. Navarro VJ and Senior JR: Drug-related hepatotoxicity. N Engl J Med 354: 731-739, 2006.
12. Daly AK: Pharmacogenomics of adverse drug reactions. Genome Med 5: 5, 2013.
13. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, Kreutz R and Garbe E: Drug-induced liver injury: Results from the hospital-based Berlin case-control surveillance study. Br J Clin Pharmacol 79: 988-999, 2015.
14. Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, Sica L, Heyer E and Quintana-Murci L: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 27: 720, 2006.
15. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, et al: Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10: 1767-1779, 2009.
16. Chen M, Borlak J and Tong W: High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58: 388-396, 2013.
17. Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, Pestka JJ, Cantor GH, Roth RA and Ganey PE: Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A 73: 58-73, 2010.
18. Russo MW and Watkins PB: Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 126: 1477-1480, 2004.
19. Zamor PJ and Russo MW: Liver function tests and statins. Curr Opin Cardiol 26: 338-341, 2011.
20. Baig NA, Herrine SK and Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 21: 193-207, 2001.
21. Oda S and Yokoi T: Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms. Yakugaku Zasshi 135: 579-588, 2015 (In Japanese).
22. Chinese Society for Tuberculosis and Chinese Medical Association: Recommendations for diagnosis and treatment of anti-tuberculosis drug induced liver injury. Chin J Tuberc Respir Dis 36: 732-736, 2013.
23. He LN, Yang AH, Cui TY, Zhai YR, Zhang FL, Chen JX, Jin CH, Fan YW, Wu ZJ, Wang LL, et al: Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity. Xenobiotica 45: 361-372, 2015.
24. Cotreau MM, von Moltke LL and Greenblatt DJ: The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44: 33-60, 2005.
25. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR and Belder R; Pravastatin in Chronic Liver Disease Study Investigators: Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453-1463, 2007.